ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

INKT MiNK Therapeutics Inc

0.9499
0.0092 (0.98%)
07 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
MiNK Therapeutics Inc INKT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0092 0.98% 0.9499 16:43:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.9405 0.9235 0.9774 0.9301 0.9407
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202406:30GLOBEMiNK to Provide Corporate Update and First Quarter 2024..
08/4/202411:00GLOBEMiNK Therapeutics Announces Promising Preclinical Activity..
21/3/202406:26IHMARKETNEWSU.S. Index Futures Rise as Fed’s Dovish Outlook Spurs..
21/3/202406:00GLOBEMiNK Reports Fourth Quarter and Year-End 2023 Results
07/3/202406:30GLOBEMiNK to Provide Corporate Update and Fourth Quarter & Full..
05/3/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:05EDGAR2Form 8-K - Current report
14/2/202407:00EDGAR2Form 8-K - Current report
14/2/202407:00GLOBEFirst Refractory Gastric Cancer Patient Dosed in Phase 2..
06/2/202407:00GLOBEMiNK Therapeutics' AgenT-797 Shows Promising Results in the..
30/1/202407:00GLOBEMiNK’s AgenT-797 Offers New Hope in Overcoming ICI..
18/1/202419:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202306:30GLOBEImmunoScape and MiNK Therapeutics Collaborate to Accelerate..
05/12/202317:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202306:00EDGAR2Form 8-K - Current report
09/11/202306:00GLOBEMiNK Therapeutics Reports Third Quarter 2023 Results
03/11/202311:00GLOBEMiNK Therapeutics Presents Clinical Activity and Long-Term..
30/10/202307:00GLOBEMiNK to Provide Third Quarter 2023 Financial Report and..
17/10/202315:15EDGAR2Form 8-K - Current report
27/9/202308:05GLOBEMiNK Therapeutics To Present Data Update From Allogeneic..
06/9/202316:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202316:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202307:30GLOBEMiNK Therapeutics to Participate in September Investor..
11/8/202306:44EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/8/202306:30EDGAR2Form 8-K - Current report
10/8/202306:30GLOBEMiNK Therapeutics Reports Second Quarter 2023 Results
10/8/202306:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28/7/202307:30GLOBEMiNK to Provide Second Quarter 2023 Financial Report and..
05/6/202306:30GLOBEMiNK Therapeutics Announces Virtual Annual Shareholders..
22/5/202307:30GLOBEMiNK Presents Clinical Data on Allogeneic iNKT Cells..
18/5/202307:30GLOBEMiNK's Novel FAP-CAR-iNKT Presented at ASGCT
11/5/202307:00GLOBEMiNK Therapeutics Reports Corporate Update and First Quarter..

Su Consulta Reciente

Delayed Upgrade Clock